Prodrug of melphalan
- TRADE NAME: Pepaxto (Oncopeptides)
- INDICATIONS: Relapsed or refractory multiple myeloma (in combination with dexamethasone)
- SYNONYM: Melflufen
- CLASS: Alkylating agent
- HALF-LIFE: 70 minutes
- FDA APPROVAL DATE: 02/26/2021
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known - PREGNANCY: Based on its mechanism of action, melphalan flufenamide can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 08/20/2025
